Latest Breaking News On - Ignacio melero - Page 1 : comparemela.com

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

CAMBRIDGE, Mass., April 24, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1.

United kingdomUnited statesJeffrey jonesRose weldonIgnacio meleroAmerican society of clinical oncologyCullinan therapeutics incExchange commissionClinical oncologyAnnual meetingChief medical officerDevelopmental therapeuticsPrivate securities litigation reform actAnnual report

Mestag Therapeutics Ltd : Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

Mestag Therapeutics Ltd : Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesUnited kingdomFrance generalRegion flamandeJudah folkmanSidney kimmelJeffreyl browningSusan hillMerck seronoBristol myers squibbElizabethm jaffeeJohns hopkins bayviewJulier brahmerIgnacio meleroGabriele bergers

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ignacio meleroPhil lhuillierCatalym gmbOncology congressDepartment of immunologyInternational coordinating investigator profEuropean society for medical oncologyTrophic communicationsObjective response ratesTed human effector cell relocation phaseEuropean societyMedical oncologyImmuno oncology congressGrowth differentiationInternational coordinating investigatorUniversidad de navarra

Researchers in Spain search for better immunotherapy mixture to fight liver cancer

RESEARCHERS at Navarra's Cima University believe that a new combination of immunotherapy treatment could be used to fight liver cancer, and are testing

Ignacio meleroNavarra cima universityCima university

Spanish researchers develop new immunotherapy combination for liver cancer

Spanish researchers at Cima University of Navarra have developed a new immunotherapy combination that improves efficacy in animal models of hepatocellular carcinoma. This is a proof of concept that lays the foundations for the application of this treatment in patients with the most common liver cancer.

New yorkUnited statesLily ramseyCarmen ochoaIgnacio meleroSaray garasaAmaia lujambioCancer center clMark foundation for cancer researchCima university of navarraSpanish association against cancerFero foundationImmunotherapy programCima universityImage creditMount sinai hospital